CRBP241220P25000
- 7.14
- 0.000.00%
Corbus Pharmaceuticals Newsroom
Promising Potential of Corbus Pharmaceuticals: Buy Rating Reinforced by Key Assets and Strategic Focus
Express News | Corbus Pharmaceuticals Announces Dosing of First Patient in Its First-in-Human Study of Crb-601 to Treat Patients With Advanced Solid Tumors
Corbus Pharmaceuticals Announces Dosing of First Patient in Its First-In-Human Study of CRB-601 to Treat Patients With Advanced Solid Tumors
Corbus Pharmaceuticals Receives Fast Track From FDA for Cervical Cancer Treatment
Corbus Pharmaceuticals Announces U.S. FDA Granted FTD to CRB-701
Express News | Corbus Pharmaceuticals Holdings Inc - First Data From Dose Escalation Study Expected in Q1 2025
Express News | FDA Grants Fast Track Designation to Crb-701 for the Treatment of Relapsed or Refractory Metastatic Cervical Cancer
FDA Grants Fast Track Designation to CRB-701 for the Treatment of Relapsed or Refractory Metastatic Cervical Cancer
Corbus Pharmaceuticals Price Target Announced at $35.00/Share by Piper Sandler
Corbus Pharmaceuticals Analyst Ratings
Piper Sandler Initiates Corbus Pharmaceuticals(CRBP.US) With Buy Rating, Announces Target Price $35
Express News | Corbus Pharmaceuticals Holdings Inc : Piper Sandler Initiates Coverage With Overweight Rating; Price Target $35
Corbus Pharmaceuticals Holdings, Inc. (CRBP): An Oversold Healthcare Stock to Invest In Now
Corbus Pharmaceuticals to Present at the 7th Annual Evercore HealthCONx Conference
Corbus Pharmaceuticals to Present at the Jefferies London Healthcare Conference
We're Not Very Worried About Corbus Pharmaceuticals Holdings' (NASDAQ:CRBP) Cash Burn Rate
RBC Capital Maintains Corbus Pharmaceuticals(CRBP.US) With Buy Rating, Cuts Target Price to $65
Corbus Pharmaceuticals (CRBP) Receives a Buy From RBC Capital
Oppenheimer Maintains Corbus Pharmaceuticals(CRBP.US) With Buy Rating, Maintains Target Price $60
Corbus Pharmaceuticals | 10-Q: Q3 2024 Earnings Report